| Literature DB >> 21960891 |
Miles P Sparrow, Peter M Irving, Leonard Baidoo, Brian Bressler, Adam S Cheifetz, Shane M Devlin, Laura E Harrell, Jennifer Jones, Patricia L Kozuch, Gil Y Melmed, Fernando S Velayos, Corey A Siegel.
Abstract
In March 2008, a roundtable discussion was convened by the inflammatory bowel disease (IBD) specialist panel the BRIDGe (Building Resources and Research in IBD Globally) group, which consists of junior faculty gastroenterologists who have undergone advanced fellowship training at IBD referral centers in the United States, Canada, the United Kingdom, and Australia. An agenda was formulated to discuss three current controversies in Crohn's disease management: the role of 5-aminosalicylates, the use of biologic combination therapy versus monotherapy, and the use of step-up therapy versus top-down therapy for Crohn's disease. The aim of the meeting was three-fold: to review the data pertaining to each topic; to collect opinions from the participants as to their analysis of the literature and their current practice; and, where possible, to formulate recommendations of current best practice given the available evidence. This manuscript summarizes the discussions on these three areas of controversy in the current management of Crohn's disease.Entities:
Keywords: 5-aminosalicylates; Crohn's disease; Inflammatory bowel disease; biologic therapies; immunomodulators
Year: 2008 PMID: 21960891 PMCID: PMC3104182
Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN: 1554-7914